In PNAS this week: recurrent deletions in mesothelioma patients, mutagenesis screen for genes working with PTEN in triple-negative breast cancer, and more.
Studies presented at the recent SITC annual meeting indicate the company's MALDI-based proteomic tests could help guide checkpoint inhibitor treatment.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
The Taiwanese research team that developed the method showed in a new study that it could better detect BRAF mutations than conventional PCR plus Sanger sequencing.
A University of Toronto team developed the probes to improve upon its previously described electrochemical clamp assay technology.
The company said it is confident it can address the state health department's concerns and will reapply for approval as soon as possible.
The results, if confirmed further, could help pick out unresponsive patients early, opening up other therapeutic options for them.
By comparing pre-treatment and post-relapse samples from vemurafenib-treated melanoma patients, researchers uncovered resistance-related cohesin complex mutations.
The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.
In Nature this week: rare variants contribute little risk to type 2 diabetes, atlas of gene expression in developing primate brain, and more.
In Science this week: genetic analysis of pollutant-tolerant fish, and more.
Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.
New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.
NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.